Novo Nordisk A/S vs Unilever PLC: Strategic Comparison
Key Differences at a Glance
| Field | Novo Nordisk A/S | Unilever PLC |
|---|---|---|
| Revenue | $46.0B | $54.9B |
| Founded | 1989 | 1929 |
| Employees | 69,505 | 125,000 |
| Market Cap | $550.0B | $151.9B |
| Headquarters | Denmark | United Kingdom |
Quick Stats Comparison
| Metric | Novo Nordisk A/S | Unilever PLC |
|---|---|---|
| Revenue | $46.0B | $54.9B |
| Founded | 1989 | 1929 |
| Headquarters | Bagsvaerd, Denmark | London, United Kingdom |
| Market Cap | $550.0B | $151.9B |
| Employees | 69,505 | 125,000 |
Novo Nordisk A/S Revenue vs Unilever PLC Revenue — Year by Year
| Year | Novo Nordisk A/S | Unilever PLC | Leader |
|---|---|---|---|
| 2025 | $46.0B | $54.9B | Unilever PLC |
| 2024 | $42.7B | $66.1B | Unilever PLC |
| 2023 | $34.0B | $64.8B | Unilever PLC |
Business Model Breakdown
Overview: Novo Nordisk A/S vs Unilever PLC
This in-depth comparison examines Novo Nordisk A/S and Unilever PLC across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Novo Nordisk A/S on its own, evaluating Unilever PLC, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Novo Nordisk A/S and Unilever PLC is widest.
On the headline numbers, Novo Nordisk A/S reports annual revenue of $46.0B against $54.9B for Unilever PLC, while their respective market capitalizations stand at $550.0B and $151.9B. Novo Nordisk A/S is headquartered in Denmark and Unilever PLC operates from United Kingdom, and those different home markets shape how each company competes.
Novo Nordisk A/S: Novo Nordisk A/S is a public company listed on NYSE under ticker NVO. Novo Nordisk makes money by developing and selling prescription medicines for diabetes, obesity, rare blood disorders, rare endocrine disorders, and related chronic diseases.
Unilever PLC: Unilever used to be described by breadth: hundreds of brands, many categories, many countries. The current strategy is the opposite: fewer brands, clearer ownership, more disciplined capital allocation, and a portfolio tilted toward higher-growth personal care and beauty.
Business Models: How Novo Nordisk A/S and Unilever PLC Make Money
Novo Nordisk A/S and Unilever PLC pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Novo Nordisk A/S and Unilever PLC.
Novo Nordisk A/S business model: Novo Nordisk makes money by developing and selling prescription medicines for diabetes, obesity, rare blood disorders, rare endocrine disorders, and related chronic diseases.
Unilever PLC business model: Unilever makes money by building and distributing branded consumer products through supermarkets, drugstores, convenience channels, emerging-market distributors, e-commerce, foodservice, and direct or prestige beauty channels. Scale in procurement, manufacturing, media buying, and route-to-market supports margins.
Competitive Advantage: Novo Nordisk A/S vs Unilever PLC
The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Novo Nordisk A/S stack up against those of Unilever PLC.
Novo Nordisk A/S competitive advantage: Novo Nordisk's advantage is deep GLP-1 science, diabetes and obesity scale, global manufacturing, payer experience, and one of the world's strongest chronic-care franchises.
Unilever PLC competitive advantage: Unilever's advantage is a mix of trusted brands, emerging-market distribution, local manufacturing, repeat-purchase categories, Power Brand marketing scale, and deep category knowledge in personal care, home care, beauty, and foods.
Growth Strategy: Where Novo Nordisk A/S and Unilever PLC Are Headed
Future prospects matter as much as current results. The growth strategies below explain how Novo Nordisk A/S and Unilever PLC each plan to expand from here.
Novo Nordisk A/S growth strategy: Novo Nordisk A/S's growth strategy centers on this advantage: Novo Nordisk's advantage is deep GLP-1 science, diabetes and obesity scale, global manufacturing, payer experience, and one of the world's strongest chronic-care franchises.
Unilever PLC growth strategy: Unilever is concentrating investment behind Power Brands, simplifying SKUs, growing beauty and wellbeing, improving execution in emerging markets, using social and digital marketing more aggressively, and reshaping the portfolio through divestitures and acquisitions.
Financial Picture: Novo Nordisk A/S vs Unilever PLC
A closer look at the financial trajectory of Novo Nordisk A/S and Unilever PLC rounds out the comparison.
Novo Nordisk A/S: Novo Nordisk A/S reported FY2025 revenue of DKK 309.064B (about $46.0B) and net income of DKK 102.434B (about $15.2B).
Unilever PLC: Unilever's 2025 reported turnover was EUR 50.5 billion on a continuing-operations basis after Ice Cream was treated as discontinued. Underlying sales growth was 3.5%, with 1.5% volume and 2.0% price growth. This profile converts EUR 50.5 billion at an estimated 2025 average EUR/USD rate of 1.0875 for USD comparison.
Company-Specific SWOT Notes
Novo Nordisk A/S
Novo Nordisk has global scale, clinical depth, and manufacturing experience in diabetes and obesity GLP-1 medicines.
A large share of investor expectations depends on continued Ozempic and Wegovy growth.
Obesity care, cardiovascular outcomes, oral formulations, and broader metabolic indications can expand the addressable market.
Rival incretin drugs, compounding, payer restrictions, safety scrutiny, and supply constraints can pressure growth.
Unilever PLC
Unilever's advantage is a mix of trusted brands, emerging-market distribution, local manufacturing, repeat-purchase categories, Power Brand marketing scale, and deep category knowledge in personal care, home care, beauty, and foods.
Unilever wins when trusted brands, local distribution, and repeat-purchase categories let it defend price premiums while reaching households at huge scale.
The biggest risk is that portfolio simplification and the Ice Cream demerger distract management while private labels and local challengers take share.
Unilever is concentrating investment behind Power Brands, simplifying SKUs, growing beauty and wellbeing, improving execution in emerging markets, using social and digital marketing more aggressively, and reshaping the portfolio through divestitures and acquisitions.
Head-to-Head Scorecard
| Category | Winner | Why |
|---|---|---|
| Revenue Scale | Unilever PLC | Unilever PLC reports the larger revenue base ($54.9B), which serves as a core operational scale signal. |
| Profitability Potential | Comparable | Both organizations prioritize market penetration or are at equivalent reporting tiers. |
| Company Age | Unilever PLC | Founded in 1989 vs 1929. The earlier pioneer typically commands longer historical institutional legacy. |
| Innovation Moat | Tied | Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity. |
| Scale (Employees) | Unilever PLC | A significantly larger reported workforce supports enhanced global distribution capability. |
| Market Cap | Novo Nordisk A/S | Higher public valuation denotes greater forward-looking investor conviction in earnings potential. |
| Future Outlook | Tied | Strategic auditing assesses that both maintain defensive leadership vectors within their core market clusters. |
Who Wins Each Category?
Unilever PLC reports the larger revenue base ($54.9B), which serves as a core operational scale signal.
Both organizations prioritize market penetration or are at equivalent reporting tiers.
Founded in 1989 vs 1929. The earlier pioneer typically commands longer historical institutional legacy.
Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity.
A significantly larger reported workforce supports enhanced global distribution capability.
Who Wins: Novo Nordisk A/S or Unilever PLC?
Reviewed by Swet Parvadiya, May 2026 - Author Profile
Our analysts compile business strategy profiles from public financial filings, press releases, and analyst reports. Each profile is reviewed for accuracy before publication by our editorial desk and updated on a rolling basis.
Frequently Asked Questions: Novo Nordisk A/S vs Unilever PLC
Is Novo Nordisk A/S better than Unilever PLC?
Verdict: Between Novo Nordisk A/S and Unilever PLC, Unilever PLC is the stronger overall option based on higher annual revenue. The decision still depends on which factors matter most for your needs, but on the weight of the evidence above, Unilever PLC comes out ahead in this Novo Nordisk A/S vs Unilever PLC comparison.
Who earns more — Novo Nordisk A/S or Unilever PLC?
Unilever PLC earns more with $54.9B in annual revenue versus Novo Nordisk A/S's $46.0B. Unilever PLC leads on total revenue based on latest verified figures.
Which company has higher revenue — Novo Nordisk A/S or Unilever PLC?
Novo Nordisk A/S reported $46.0B, while Unilever PLC reported $54.9B. The revenue leader is Unilever PLC based on latest verified figures.
Novo Nordisk A/S revenue vs Unilever PLC revenue — which is higher?
Novo Nordisk A/S revenue: $46.0B. Unilever PLC revenue: $46.0B. Unilever PLC has the larger revenue base of the two companies.
Sources & References
- Novo Nordisk A/S Corporate Website
- Novo Nordisk A/S Annual Report 2025 - Revenue and Financial Data
- sec.gov
- novonordisk.com
- Unilever PLC Corporate Website
- Unilever PLC Annual Report 2025 - Revenue and Financial Data
- unilever.com
- unilever.com
- unilever.com
- unilever.com